10
Jun
2021

Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

The Variant on the Move
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Pfizer’s Game-Changer, Moderna-NIH Feud Goes Public, & Genomics England Ends Dx Odysseys
The Vaccine Pile-Up, Regeneron Crushes It, CF Foundation Bets on Flagship Combos